Eur J Surg Oncol: Early evaluation of magnetic resonance imaging predicts the pathological response of triple negative breast cancer to new complementary chemotherapy.

The ability of breast magnetic resonance imaging (MRI) to predict pathological total remission (pCR) of new assisted system therapy (NST) varies from biological substation to biological substation.
study was conducted to determine the correlation between breast MRI results after the initial treatment of phase III BrighTNess and pCR in patients with triple negative breast cancer (TNBC).
collected imaging and pathological response data for 519 phase II-III TNBC patients who performed NST in accordance with the protocol.
mrI total remission (mCR) is defined as the disappearance of all target lesions, and mrI partial remission (mPR) is a reduction of up to 50% in the maximum tumor diameter.
overall, 116 patients (22%) showed mCR, while 166 (32%) had mPR and 237 (46%) had stable/progressive diseases (SD/PD).
positive predictions (PPV), negative predictions, and overall accuracy of MRI to pCR in the medium term were 78%, 56%, and 61%, respectively, and there was no significant difference in accuracy between gBRCA mutant carriers and non-carriers (52% vs. 63%, p .10).
patients with mPR or mcR were 3.35 times more likely to develop pCR during surgery (95% CI 2.07-5.41) than patients with SD/PD.
treatment, mrI response during NST was significantly associated with breast preservation surgery eligibility (mCR was 93.1% vs. SD/PD was 81.6%, P .lt;0.001).
, in the BrighTNess trial, a complete remission of the medium-term MRI showed a PCR PPV of 78% after TNBC completed NST.
, a significant proportion of mPR or SD/PD patients also achieve pCR.
.